Drug Profile
Research programme: neuromuscular disorders therapeutics - Curia/NINDS
Latest Information Update: 13 Oct 2021
Price :
$50
*
At a glance
- Originator AMRI; National Institute of Neurological Disorders and Stroke
- Developer Curia; National Institute of Neurological Disorders and Stroke
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Spinal muscular atrophy
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Spinal-muscular-atrophy in USA
- 19 Aug 2011 AMRI receives federal grant from the National Institutes of Health (NIH)/National Institute of Neurological Disorders and Stroke (NINDS) for drug development in Spinal muscular atrophy
- 21 Jul 2005 Preclinical trials in Spinal muscular atrophy in USA (unspecified route)